ARS Pharmaceuticals Soar 68% in Premarket Trading as FDA Panel Backs Neffy
By Colin Kellaher
ARS Pharmaceuticals shares surged in premarket trading Friday after the biopharmaceutical company won the backing of a U.S. Food and Drug Administration advisory committee for its proposed epinephrine nasal spray for the treatment of severe allergic reaction, including anaphylaxis.
Shares of the San Diego company, which closed Wednesday at $4.52, were recently up 68% premarket to $7.60. Trading in the stock was halted during Thursday's session.
ARS late Thursday said the FDA panel voted that available data support a favorable benefit-risk assessment for the spray, which the company plans to market as "neffy," for adults and children who weigh more than 66 pounds.
ARS said neffy, if approved by the FDA, would be the first needle-free epinephrine product for severe allergic reactions.
The FDA, which usually follows the advice of its advisory committees but it isn't bound by the recommendations, has set a mid-2023 target action date for neffy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 12, 2023 08:40 ET (12:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?